ChronicleBio

No need to leave your bed! We’ll bring the research to you.

Mobile sample collection is our next chapter in expanding access to research on complex chronic conditions. Every participant receives a research report back.

Sign Up: chroniclebio.com/biobank

Today we are announcing our first clinical trial. We're joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS.

Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027.

Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio's proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond. 

We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do. 

Read More: chroniclebio.com/news/chronicle…

“This is real, tens of thousands of people are suffering,” Dr. @knidac said, “and there are things we can do to help them.”

Dr. Knight, a member of the ChronicleBio Scientific Advisory Board, and one of the leading clinical voices on Ehlers-Danlos Syndrome in the country spoke with the @nytimes this week alongside Dr. @CortDoesScience, our Principal Translational Scientist, for a piece on hypermobile Ehlers Danlos Syndrome. They see firsthand how diagnostic delays and limited treatment options have left patients suffering. With limited resources available, patients often turn to social media for answers.

“People aren’t making up symptoms just because they saw a video,” Dr. Gensemer said. “They’re actually finding words to describe things that have been wrong their whole life.”

hEDS is a chronic illness at the center of our research. Many patients with the condition also develop POTS, ME/CFS, MCAS, and related neuroimmune conditions. Resolve one patient into the mechanisms driving their disease and you find shared pathways across millions. That’s what we’re doing.

Read more about what patients with these conditions experience in the full New York Times piece: nytimes.com/2026/11/09/wel…

Chronic conditions have long been defined by symptoms instead of biology, hindering drug discovery that could help millions of patients.

@Forbes spoke with ChronicleBio about how we're using multi-omic analysis & AI to end trial-and-error medicine.

forbes.com/sites/amyfeldm…

Welcome to the #ChronicleBiobank, @sam_heds! 🩸 + 🧪 = 🫶